FDA Issues Guidance Prioritizing People of Color for Monoclonal Antibodies
Photo: AP Photo/LM Otero
Guidance from the Food and Drug Administration says that some people may be considered "high risk" based on their race and will be prioritized for monoclonal antibodies and oral antivirals used to treat COVID-19.
The agency issued a fact sheet for healthcare providers, which was updated in December, notifying them that it had approved emergency use authorizations of sotrovimab, a monoclonal antibody proven effective against omicron. However, the antibodies are only approved for patients considered to be "high risk."
"Medical conditions or factors" such as "race or ethnicity" may "place individual patients at ...